Perspective shares surge 33.11% after-hours on $175M funding to advance cancer trials, expand manufacturing.

Perspective Therapeutics (CATX) surged 33.11% in after-hours trading following the announcement of a $175 million underwritten offering of common stock and pre-funded warrants. The financing, priced at $3.79 per share and $3.789 per warrant, includes participation from major healthcare investors such as Citadel’s Surveyor Capital and Ally Bridge Group. Proceeds will advance clinical trials for radiopharmaceutical therapies targeting cancers, expand manufacturing capacity, and support working capital. The offering, expected to close on February 3, 2026, signals investor confidence in the company’s pipeline, including Phase 1/2a programs for neuroendocrine tumors, melanoma, and solid tumors. The significant capital raise directly addresses operational and developmental needs, aligning with the stock’s sharp post-announcement rally.